Trial Profile
Retrospective study of conbercept versus ranibizumab for the treatment of retinopathy of prematurity
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Sep 2018
Price :
$35
*
At a glance
- Drugs Conbercept (Primary) ; Ranibizumab (Primary)
- Indications Retinopathy of prematurity
- Focus Therapeutic Use
- 03 Sep 2018 New trial record
- 01 Aug 2018 Results published in the Retina